Holen Sie sich die Stockscreener-App
0.58
3.57%
0.02
Handel nachbörslich:
.58
Xtant Medical Holdings Inc Aktie (XTNT) Neueste Nachrichten
MSN Money - MSN
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Xtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beat - MSN
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 67.8% in April - MarketBeat
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results (PR Newswire) - Aktiellt
Xtant (XTNT) Stock Prediction | Xtant Medical posts 100% EPS surprise, beats loss estimatesTrending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai
Xtant (XTNT) Stock: Risks and Growth Potential | Q4 2025: Earnings Beat EstimatesOperating Income - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Xtant Medical (XTNT): Buy Rating and Growth Prospects Highlighted - GuruFocus
Xtant Medical Holdings, Inc. (XTNT) - Minichart
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Growth in Short Interest - MarketBeat
Xtant Medical acquires exclusive U.S. rights to HEMOBLAST Bellows By Investing.com - Investing.com Australia
Xtant Medical Holdings, Inc. and Dilon Technologies, Inc Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product - marketscreener.com
Xtant Medical Secures Exclusive U.S. Distribution Rights for Dilon’s HEMOBLAST Bellows Hemostatic Product and Expands Sales Team - Minichart
Xtant Medical Expands Portfolio with HEMOBLAST Distribution Deal - TipRanks
Xtant Medical acquires exclusive U.S. rights to HEMOBLAST Bellows - Investing.com
Xtant Medical (XTNT) pays $5M for exclusive U.S. HEMOBLAST rights, adds 20 sales staff - Stock Titan
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product - PR Newswire
Breakout Move: Can Xtant Medical Holdings Inc outperform under higher oil pricesTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Sentiment Watch: Is Xtant Medical Holdings Inc stock overvalued or fairly priced2026 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
Meme Stocks: Can Xtant Medical Holdings Inc deliver consistent dividends2026 Stock Rankings & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial - Financial Times
Craig-Hallum Maintains Buy on Xtant Medical Holdings, Inc. (XTNT) March 2026 - Meyka
XTNT PE Ratio & Valuation, Is XTNT Overvalued - Intellectia AI
XTNT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Craig-Hallum Maintains Buy on Xtant Medical (XTNT) March 18, 2026 - Meyka
Xtant Medical Earnings Call Highlights Profitability Turnaround - The Globe and Mail
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results - Orthopedics This Week
Xtant Medical (NYSEAMERICAN:XTNT) Issues Quarterly Earnings Results - MarketBeat
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2025 Earnings Call Transcript - Insider Monkey
Xtant Medical Achieves Profitability and 14% Revenue Growth in 2025, Provides 2026 Outlook After Strategic Divestiture - Minichart
Xtant Medical (NYSEAMERICAN:XTNT) Price Target Cut to $1.00 by Analysts at BTIG Research - Defense World
Xtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll off - msn.com
Latest XTNT NewsXtant Medical Announces Debt Restructuring - Stock Titan
Xtant Medical Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
XTNT Stock Update: Analyst Lowers Price Target Amid Buy Rating | - GuruFocus
Xtant Medical Q4 2025 Earnings Call Transcript - MarketBeat
Xtant Medical Holdings, Inc. 2025 Annual Report: Orthobiologics, Spinal Implants, and Company Overview - Minichart
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
XTNT: 2025 saw double-digit revenue growth and profitability, with 2026 focused on core biologics acceleration - TradingView — Track All Markets
American Shared Hospital Services (AMS) Reports Q4 Earnings - news.alphastreet.com
Xtant Medical Holdings, Inc. (XTNT) Reports In-Line Q4 Earnings - AlphaStreet
Xtant Medical Holdings 2025 10-K: $133.9M Revenue, $0.03 Diluted EPS - TradingView
XTNT: 2025 net income of $5.0M driven by one-time gains; 2026 outlook pressured by lost license revenue - TradingView — Track All Markets
Xtant Medical (NYSE: XTNT) sheds one-time 2025 gains, sells Coflex/CoFix assets - Stock Titan
Xtant Medical Holdings reports FY2025 revenue $133.9M, net income $5.0M and adjusted EBITDA $16.3M - TradingView
XTNT: 2025 saw 14% revenue growth, profitability, and a strategic shift to core biologics - TradingView — Track All Markets
Form 8-KCurrent report - ADVFN
Xtant Medical Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
0.41%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):